Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis

Samuel F Hunter; Jas Bindra; Ishveen Chopra; John Niewoehner; Mary P Panaccio; George J Wan

doi:10.2147/CEOR.S330118

Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis

Clinicoecon Outcomes Res. 2021 Oct 11:13:883-892. doi: 10.2147/CEOR.S330118. eCollection 2021.

Authors

Samuel F Hunter¹, Jas Bindra², Ishveen Chopra³, John Niewoehner⁴, Mary P Panaccio⁴, George J Wan⁴

Affiliations

¹ Advanced Neurosciences Institute, Franklin, TN, USA.
² Falcon Research Group, North Potomac, MD, USA.
³ Manticore Consultancy, Bethesda, MD, USA.
⁴ Mallinckrodt Pharmaceuticals, Hampton, NJ, USA.

Abstract

Background: Relapses are common among patients with multiple sclerosis (MS) despite treatment with disease-modifying therapies. Repository corticotropin injection (RCI, Acthar^® Gel), plasmapheresis (PMP), and intravenous immunoglobulin (IVIg) are alternative therapies for MS relapse. There is a dearth of economic assessments of these therapies for the acute exacerbations of MS. This study estimated the cost-effectiveness of RCI compared to PMP or IVIg.

Methods: A Markov state-transition model compared outcomes (costs, relapses, remission, and utilities) with RCI versus PMP or IVIg for the acute exacerbations in MS. The model was developed from the United States (US) payer and societal perspectives over one to three years. Patients initiated on alternative therapies were evaluated in one-day increments for the first 30 days during treatment. The model assumes the natural history of MS after treatment in the first month, adjusting for the effect of treatment. Incremental cost-effectiveness ratios (ICERs) were estimated as cost per quality-adjusted life-year (QALY) gained. The uncertainty in model parameters was evaluated in probabilistic sensitivity analyses.

Results: In the base case, RCI has an ICER of USD 42,078 per QALY compared to PMP over one year from the payer perspective and is dominant over two and three years; RCI is dominant compared to PMP from the societal perspective over all three years. Compared to IVIg, RCI is a dominant strategy from both payer and societal perspectives over all three years. Probabilistic sensitivity analysis supports the base case findings, suggesting that RCI may be cost-effective versus PMP and IVIg for acute exacerbations in MS.

Conclusion: RCI is a cost-effective alternative treatment for MS relapses compared to PMP and IVIg from the US payer and societal perspectives.

Keywords: Acthar® Gel; acute exacerbation; cost-effectiveness analysis; multiple sclerosis; quality-adjusted life-year; repository corticotropin injection.

Grants and funding

This study was sponsored by Mallinckrodt Pharmaceuticals. The article processing charges and open access fee for this publication were funded by Mallinckrodt Pharmaceuticals.